These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35228392)

  • 1. ETV6 Regulates Hemin-Induced Erythroid Differentiation of K562 Cells through Mediating the Raf/MEK/ERK Pathway.
    Li Z; Sun MZ; Lv X; Guo C; Liu S
    Biol Pharm Bull; 2022; 45(3):250-259. PubMed ID: 35228392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRKL but not CRKII contributes to hemin-induced erythroid differentiation of CML.
    Guo C; Lv X; Zhang Q; Yi L; Ren Y; Li Z; Yan J; Zheng S; Sun MZ; Liu S
    J Cell Mol Med; 2024 May; 28(9):e18308. PubMed ID: 38683131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK signaling pathway is differentially involved in erythroid differentiation of K562 cells depending on time and the inducing agent.
    Woessmann W; Zwanzger D; Borkhardt A
    Cell Biol Int; 2004; 28(5):403-10. PubMed ID: 15193284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
    Sumi K; Tago K; Nakazawa Y; Takahashi K; Ohe T; Mashino T; Funakoshi-Tago M
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of ERK activation in growth and erythroid differentiation of K562 cells.
    Woessmann W; Mivechi NF
    Exp Cell Res; 2001 Apr; 264(2):193-200. PubMed ID: 11262176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Akt regulates vitamin D3-induced leukemia cell functional differentiation via Raf/MEK/ERK MAPK signaling.
    Wang J; Zhao Y; Kauss MA; Spindel S; Lian H
    Eur J Cell Biol; 2009 Feb; 88(2):103-15. PubMed ID: 19058874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway.
    Kang SK; Lee JY; Chung TW; Kim CH
    FEBS Lett; 2004 Nov; 577(3):361-6. PubMed ID: 15556610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
    Yang Y; Liu X; Xiao F; Xue S; Xu Q; Yin Y; Sun H; Xu J; Wang H; Zhang Q; Wang H; Wang L
    PLoS One; 2015; 10(2):e0117573. PubMed ID: 25688862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
    Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
    Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of G proteins and ERK activation in hemin-induced erythroid differentiation of K562 cells.
    Kucukkaya B; Arslan DO; Kan B
    Life Sci; 2006 Feb; 78(11):1217-24. PubMed ID: 16216279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALDH6A1 weakens the progression of colon cancer via modulating the RAS/RAF/MEK/ERK pathway in cancer cell lines.
    Li X; Wang N; Wu Y; Liu Y; Wang R
    Gene; 2022 Oct; 842():146757. PubMed ID: 35907565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Chappell WH; Abrams SL; Wong EW; Chang F; Lehmann B; Terrian DM; Milella M; Tafuri A; Stivala F; Libra M; Basecke J; Evangelisti C; Martelli AM; Franklin RA
    Biochim Biophys Acta; 2007 Aug; 1773(8):1263-84. PubMed ID: 17126425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of THAP11 on erythroid differentiation and megakaryocytic differentiation of K562 cells.
    Kong XZ; Yin RH; Ning HM; Zheng WW; Dong XM; Yang Y; Xu FF; Li JJ; Zhan YQ; Yu M; Ge CH; Zhang JH; Chen H; Li CY; Yang XM
    PLoS One; 2014; 9(3):e91557. PubMed ID: 24637716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutive activation of the MEK/ERK pathway mediates all effects of oncogenic H-ras expression in primary erythroid progenitors.
    Zhang J; Lodish HF
    Blood; 2004 Sep; 104(6):1679-87. PubMed ID: 15166036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
    Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
    J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of ERK accelerates erythroid differentiation of K562 cells induced by herbimycin A and STI571 while activation of MEK1 interferes with it.
    Kawano T; Horiguchi-Yamada J; Iwase S; Furukawa Y; Kano Y; Yamada H
    Mol Cell Biochem; 2004 Mar; 258(1-2):25-33. PubMed ID: 15030167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.